Oncolytics Biotech Inc. (Oncolytics Biotech) is focused on the discovery and development of oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional therapeutics. The product that the Company is developing may represent a treatment for Ras mediated cancers, which can be used as an alternative to existing cytotoxic or cytostatic therapies or as an adjuvant therapy to conventional chemotherapy, radiation therapy, or surgical resections. It could also potentially be used to treat certain cellular proliferative disorders for which no therapy exists. Oncolytics Biotech is also assessing the potential opportunities for product candidates resulting from issued patents received for Ras targeted adenovirus and herpes virus. Oncolytics Biotech Inc is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company's potential product for human use, Reolysin, is developed from the reovirus. The functionality of the product is based upon the finding that tumors bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response mediated by the host cellular protein, PKR.